12:00 AM
May 13, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Incivo telaprevir regulatory update

EMA's CHMP issued a positive opinion recommending approval of twice-daily dosing of Incivo telaprevir from Johnson & Johnson to treat chronic genotype 1 HCV infection in combination with peginterferon and ribavirin. The small molecule HCV NS3/4A protease inhibitor is...

Read the full 171 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >